Skip to main content

Advertisement

SpringerLink
Log in

Distribution of serum βCTX in a population-based study of postmenopausal women taking into account different anti-osteoporotic therapies (the FRODOS Cohort)

  • Original article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

This cross-sectional study evaluated the distribution of serum cross-linked C-telopeptides of collagen type I (βCTXs) in postmenopausal women, the characteristics of bone remodeling, and the factors influencing this bone marker, especially the use of anti-osteoporotic drugs. Women (n = 4,175) aged 59–70 years randomly selected from the community were invited to participate, measuring βCTXs and lumbar and femoral bone mineral density at recruitment. Risk factors for osteoporosis and the use of anti-osteoporotic treatment were collected with a structured questionnaire. We evaluated the percentage of women with increased (βCTXs >0.620 ng/mL) and decreased bone turnover (βCTXs <0.100 ng/mL) and those reaching the so-called treatment target (values of βCTXs within the lower half of the reference range for healthy young premenopausal women). Two thousand nine hundred sixty-eight women (70 %) participated (2,405 non-treated and 563 treated). Increased and decreased bone turnover was observed in 16.4 and 1.8 %, respectively, of non-treated women with significant differences compared with treated women (9.7 and 14.2 %, respectively, p < 0.001); 28 % of non-treated osteoporotic individuals had increased bone turnover versus 14 % of osteopenic participants and 8.8 % of women with normal bone density (p < 0.001). Women receiving bisphosphonates presented the highest percentages of decreased bone turnover (27 %) and βCTXs (43 %) within the treatment target. Increased bone turnover is observed in 16.4 % of non-treated postmenopausal women and is more frequent in individuals with osteoporosis, whereas decreased bone turnover is unusual. Most participants taking bisphosphonates had values within the treatment target, but nearly one quarter had decreased bone turnover.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, IOF-IFCC Bone Marker Standards Working Group et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391–420

    Article  PubMed  CAS  Google Scholar 

  2. Civitelli R, Armamento-Villarreal R, Napoli M (2009) Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 20:843–851

    Article  PubMed  CAS  Google Scholar 

  3. Ivaska KK, Gerdhem P, Väänänen HK, Akesson K, Obrant KJ (2010) Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of nine years. J Bone Miner Res 25:393–403

    Article  PubMed  CAS  Google Scholar 

  4. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536

    Article  PubMed  CAS  Google Scholar 

  5. Miller PD (2007) Monitoring osteoporosis therapy. Curr Osteoporos Rep 5:38–43

    Article  PubMed  Google Scholar 

  6. Lewiecki EM (2010) Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis. Curr Osteoporos Rep 8:15–22

    Article  PubMed  Google Scholar 

  7. Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Reginster JY, Gangji V, Members of Advisory Board on Bone Markers, (2009) Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract 63:19–26

    Article  PubMed  CAS  Google Scholar 

  8. Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R (2008) Establishing a reference range for bone turnover markers in young, healthy women. Bone 42:623–630

    Article  PubMed  CAS  Google Scholar 

  9. Glover SJ, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, Cauley JA, Black DM, Delmas PD, Eastell R (2009) Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 24:389–397

    Article  PubMed  Google Scholar 

  10. Karsdal MA, Qvist P, Christiansen C, Tankó LB (2006) Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression? Drugs 66:1909–1918

    Article  PubMed  Google Scholar 

  11. Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948–2952

    Article  PubMed  CAS  Google Scholar 

  12. Epstein S (2005) The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc 80:379–388

    Article  PubMed  Google Scholar 

  13. Compston J (2007) Over-suppression of bone turnover: does it exist? Curr Osteoporos Rep 5:179–185

    Article  PubMed  Google Scholar 

  14. Kanterewicz E, Puigoriol E, Peris P, Del Río L, Rosique P, Yáñez A, Grupo de investigadores del estudio de Fracturas Osteoporóticas de Osona (2009) Relationship between C-telopeptides of type I collagen serum values with bone mineral density and antiosteoporotic drug intake in postmenopausal women. Preliminary data from the FRODOS study. Med Clin (Barc) 133:609–614

    Article  Google Scholar 

  15. Kanterewicz E, Peris P, Puigoriol E (2011) Prevalence of densitometric osteoporosis and osteopenia in Spain. Bone 48:667

    Article  PubMed  Google Scholar 

  16. Martínez J, Olmos JM, Hernández JL, Pinedo G, Llorca J, Obregón E, Valero C, González-Macías J (2009) Bone turnover markers in Spanish postmenopausal women: the Camargo cohort study. Clin Chim Acta 409:70–74

    Article  PubMed  Google Scholar 

  17. Gerdhem P, Ivaska KK, Alatalo S, Halleen JM, Hellman J, Isaksson A et al (2004) Bichemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386–393

    Article  PubMed  CAS  Google Scholar 

  18. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254

    PubMed  CAS  Google Scholar 

  19. Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, Seibel MJ (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14:792–801

    Article  PubMed  CAS  Google Scholar 

  20. Luz Rentero M, Carbonell C, Casillas M, González Béjar M, Berenguer R (2008) Risk factors for osteoporosis and fractures in postmenopausal women between 50 and 65 years of age in a primary care setting in Spain: a questionnaire. Open Rheumatol J 2:58–63

    Article  PubMed  Google Scholar 

  21. Langsetmo LA, Morin S, Richards JB, Davison KS, Olszynski WP, Prior JC, Josse R, Goltzman D, CaMos Research Group (2009) Effectiveness of antiresorptives for the prevention of nonvertebral low-trauma fractures in a population-based cohort of women. Osteoporos Int 20:283–290

    Article  PubMed  CAS  Google Scholar 

  22. Rohr CI, Sarkar A, Barber KR, Clements JM (2004) Prevalence of prevention and treatment modalities used in populations at risk of osteoporosis. J Am Osteopath Assoc 104:281–287

    PubMed  Google Scholar 

  23. Minisola S, Del Fiacco R, Piemonte S, Iorio M, Mascia ML, Fidanza F et al (2008) Biochemical markers in glucocorticoid-induced osteoporosis. J Endocrinol Invest 31(7 Suppl):28–32

    PubMed  CAS  Google Scholar 

  24. Reyes-García R, Rozas-Moreno P, López-Gallardo G, García-Martín A, Varsavsky M, Avilés-Perez MD, Muñoz-Torres M (2011) Serum levels of bone resorption markers are decreased in patients with type 2 diabetes. Acta Diabetol. doi:10.1007/s00592-011-0347-0

    PubMed  Google Scholar 

  25. Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Solomon DH (2008) Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 148:637–646

    PubMed  Google Scholar 

  26. Eisman J, Clapham S, Kehoe L (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian Bone Care Study. J Bone Miner Res 19:1969–1975

    Article  PubMed  Google Scholar 

  27. Ettinger B, Barrett-Connor E, Hoq LA, Vader JP, Dubois RW (2006) When is it appropriate to prescribe postmenopausal hormone therapy? Menopause 13:404–410

    Article  PubMed  Google Scholar 

  28. Eekman DA, Bultink IE, Heijboer AC, Dijkmans BA, Lems WF (2011) Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet Disord 12:167

    Article  PubMed  Google Scholar 

  29. Peris P, Torra M, Olivares V, Reyes R, Monegal A, Martínez-Ferrer A, Guañabens N (2011) Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone 49:706–709

    Article  PubMed  CAS  Google Scholar 

  30. Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH et al (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444–3450

    Article  PubMed  CAS  Google Scholar 

  31. Delmas PD, Davis SR, Hensen J, Adami S, van Os S, Nijland EA (2008) Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporos Int 19:1153–1160

    Article  PubMed  CAS  Google Scholar 

  32. Landfeldt E, Ström O, Robbins S, Borgström F (2012) Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23:433–443

    Article  PubMed  CAS  Google Scholar 

  33. Rogers A, Glover SJ, Eastell R (2009) A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone 45:1044–1052

    Article  PubMed  CAS  Google Scholar 

  34. Thomas SD, Need AG, Nordin BE (2010) Suppression of C-terminal telopeptide in hypovitaminosis D requires calcium as well as vitamin D. Calcif Tissue Int 86:367–374

    Article  PubMed  CAS  Google Scholar 

  35. Kruger MC, Schollum LM, Kuhn-Sherlock B, Hestiantoro A, Wijanto P, Li-Yu J, Agdeppa I, Todd JM, Eastell R (2010) The effect of a fortified milk drink on vitamin D status and bone turnover in post-menopausal women from South East Asia. Bone 46:759–767

    Article  PubMed  CAS  Google Scholar 

  36. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141–151

    Article  PubMed  CAS  Google Scholar 

  37. Berecki-Gisolf J, Hochey R, Dobson A (2008) Adherence to bisphosphonate treatment by elderly women. Menopause 15:984–990

    Article  PubMed  Google Scholar 

  38. Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MC, Klee G et al (2000) Clinical use of biochemical markers of bone remodelling: current status and future directions. Osteoporos Int 11:467–480

    Article  PubMed  CAS  Google Scholar 

  39. Melton LJ III, Khosla S, Atkinson EJ, O’Fallon WM, Riggs BL (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12:1083–1091

    Article  PubMed  Google Scholar 

  40. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R, HORIZON-PFT Research Group (2009) Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 24:1544–1551

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant (PI05/1430) from the Spanish “Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III”. Roche Diagnostics kindly provided reagents to determine βCTXs.

Conflict of interest

All authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. Rheumatology Unit, Hospital General de Vic, C/Francesc Pla, 1, 08500, Vic (Barcelona), Spain

    Eduardo Kanterewicz

  2. Rheumatology Service, Hospital Clínic i Provincial, CIBERehd, Barcelona, Spain

    Pilar Peris

  3. Epidemiology Unit, Hospital General de Vic, Vic (Barcelona), Spain

    Emma Puigoriol

  4. Epidemiology Unit, Fundació Caubet-Cimera, Balearic Islands, Spain

    Aina Yáñez

  5. Biochemistry Laboratory, Hospital General de Vic, Vic (Barcelona), Spain

    Pau Rosique

  6. Densitometry Unit, CETIR Centre Mèdic, Barcelona, Spain

    Luis del Rio

Authors
  1. Eduardo Kanterewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pilar Peris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emma Puigoriol
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aina Yáñez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pau Rosique
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luis del Rio
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

FRODOS Research Group

Corresponding author

Correspondence to Eduardo Kanterewicz.

Additional information

Members of the FRODOS Research Group are given in Appendix.

Appendix: FRODOS Research Group

Appendix: FRODOS Research Group

Dr. Toni Iruela (EAP Centelles), Dr. Xavier Farrés (EAP Vic Sud), Dr. Sara Martínez (CAP Osona), Dr. Maria Vilamú (CAP Manlleu), Dr. Consol Sánchez (CAP Torelló), Dr. Núria de la Iglesia (Consultori Local St Vicenç de Torelló), Dr. Josep Fontarnau (Consultori Local St Pere de Torelló), Dr. Vicenç Canal (CAP Roda de Ter), Dr. Xavier Costa (CAP Tona), Dr. Vicenç Coma (Consultori Local Seva), Dr. Assumpta Farràs (Consultori Local St Miquel de Balenyà), Dr. Lourdes Piñol (CAP St Hipolit de Voltregà), Dr. Rosa Maria Salla (CAP Sta Eugenia de Berga),

Dr. Anna Puente (Consultori Local Taradell), Dr. Marta Cantero (Consultori Local St Julià de Vilatorta), Dr. Carles Blay (Consultori Local Calldetenes), Dr. Anna Ribas (Consultori Local Folgueroles), Dr. Jordi Espinàs (Consultori Local Viladrau), Jordi Oliva (CAP Sta Eugenia de Berga), Dr. Tomàs Morelló (CAP St Quirze de Besora), Dr. Anna Ramos (CAP St Quirze de Besora), Dr. Pere Munt (Consultori de Montesquiu), Dr. Dani Montanyà (Consultori St Boi de Lluçanès), Dr. Josep Mª Garcia Talavera (CAP Prats de Lluçanès), Dr. Raimon Codina (CAP Prats de Lluçanès), Dr. Francesc Olivé (Consultori d’Olost), Dr. Miquel Casadevall (Consultori St Bartomeu del Grau), Judit Solà (Epidemiology Unit-Consorci Hospitalari de Vic).

About this article

Cite this article

Kanterewicz, E., Peris, P., Puigoriol, E. et al. Distribution of serum βCTX in a population-based study of postmenopausal women taking into account different anti-osteoporotic therapies (the FRODOS Cohort). J Bone Miner Metab 31, 231–239 (2013). https://doi.org/10.1007/s00774-012-0410-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-012-0410-0

Keywords

Search

Navigation